News

UKPIN Statement on vCJD Risk in recipients of Normal Human Immunoglobulin

Nov 11, 2017
8 November 2017
Patients who received UK-sourced immunoglobulin should not be treated any differently from others who are not at risk, with regard to endoscopic or any other procedures. This is a view shared by the United Kingdom Primary Immunodeficiency Network (UKPIN) and the National CJD Research & Surveillance Unit (NCJDRSU), as well as with international experts in immunodeficiency. See Resource links for full statement
undefined